The UK Space Agency and senior representatives from the Swiss pharmaceutical sector have joined forces. They have done so to shape the commercial future of space-enabled pharma development.
The move follows the inaugural UK-Swiss Microgravity Biopharma Dialogue at the British Embassy in Berne. International leaders from government, healthcare, space technology, and investment convened to address the commercial and regulatory barriers facing in-orbit drug discovery and manufacturing.
Space-Enabled Pharma: Unlocking a $300 Billion R&D Market
The global pharmaceutical sector investing approximately $300 billion (£230 billion) in research and development annually. Microgravity environments offer unprecedented opportunities. Conducting biopharma research in space could significantly improve R&D efficiency, trial speed, and drug formulation success rates, delivering substantial economic benefits while accelerating life-saving therapies.
However, translating orbital scientific breakthroughs into commercially viable products on Earth requires clear regulatory pathways and solid evidence of value.
A spokesperson at the UK Space Agency said: “Bringing together healthcare providers, regulators, and industry helps ensure innovation is driven by genuine user needs and underpinned by the evidence needed to support adoption at scale.”
4 Pillars for Commercial In-Orbit Manufacturing
Rather than focusing solely on scientific potential, dialogue participants targeted the practical steps needed to inform corporate investment decisions. Four core themes emerged from the summit:
Evidence of Value: Developing a repeatable, broader body of evidence demonstrating microgravity’s clear advantages over terrestrial manufacturing.
Standardised Frameworks: Establishing shared protocols for documenting and sharing data across international regulators, investors, and industry bodies.
Regulatory Clarity: Defining how existing regulatory framework apply to in-orbit manufacturing to boost investor confidence.
Sector Awareness: Educating pharmaceutical commercial leaders on the quantifiable benefits and operational limitations of microgravity.
Pioneering Regulatory Pathways
To build commercial confidence, the UK Space Agency is working alongside the Medicines and Healthcare products Regulatory Agency (MHRA), the Civil Aviation Authority, and the Regulatory Innovation Office. Recent joint statements confirm that existing UK regulatory frameworks provide a credible foundation for in-orbit pharmaceutical manufacturing.
Additionally, funding from the UKSA’s Unlocking Space Portfolio supported the BioOrbit PHARM feasibility study, which evaluated end-to-end mission requirements and regulatory touchpoints for manufacturing drugs in space.
Next Steps: Autumn 2026 Roadmap
With In-Orbit Servicing, Assembly, and Manufacturing (ISAM) established as one of the UK’s four Ministerial priorities for space sector growth, the UK Space Agency and MHRA will publish a formal joint regulatory roadmap in Autumn 2026.
The roadmap will map every stage of the in-orbit manufacturing lifecycle against existing UK regulations, providing global life science firms with a clear, credible route to market. The findings from the Berne dialogue will also feed into an upcoming joint white paper on space-enabled health innovation.
